Trial Profile
A Phase 1b, Double-blinded, Placebo-controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Subjects With Multiple Sclerosis (ms)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs PF 6342674 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Pfizer
- 12 Jan 2016 Planned End Date changed from 1 Jan 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
- 12 Jan 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
- 02 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.